RxDoctor Payments Data

Iqbal Bashir, MD

Cardiovascular Disease · Queensbury, NYNPI 1699793539

Payments from drug & device makers

$4,893in general payments, 2019–2025

Across 59 payments — averaging $82.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Shockwave Medical, Inc$278
  • Novartis$262
  • Baxter Healthcare$151
  • Artivion, Inc.$150
  • Pfizer$104
  • plus $408 from 13 others

What the payments were for

  • Travel & lodging$3,21266%
  • Food & beverage$1,64834%
  • Education$331%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,893 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$170,854
Medicare patients
2,328
Services billed
4,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$219,819
EntrestoSacubitril/Valsartan75$89,070
Repatha SureclickEvolocumab72$72,877
XareltoRivaroxaban40$56,341
BrilintaTicagrelor43$40,203
MultaqDronedarone Hcl21$37,441
Repatha SyringeEvolocumab40$32,442
JardianceEmpagliflozin31$28,819
Praluent PenAlirocumab15$16,211
Rosuvastatin Calcium451$7,488
Ranolazine ErRanolazine58$5,897
Metoprolol Succinate378$5,400
Ezetimibe140$4,508
Atorvastatin Calcium256$2,618
Losartan Potassium228$2,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$219,819191 claims
NovartisEntresto$262$89,07075 claims
Johnson & JohnsonXarelto$13$56,34140 claims
AstraZenecaBrilinta$27$40,20343 claims
Sanofi-aventis U.S. LLCMultaq$28$37,44121 claims
Boehringer IngelheimJardiance$14$28,81931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Queensbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →